The United Kingdom and the United States have concluded a key trade agreement that will keep no duties on British drug exports going into the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to raise funding on drugs through the NHS. This commitment guarantees that duties on these vital products will remain at zero for a period of three years.
This deal is in response to previous threats to significantly raise tariffs on patented drug products, with figures discussed as high as one hundred percent.
"This arrangement with the Britain reinforces the worldwide climate for new treatments and establishes much-needed equity to transatlantic medicine commerce," a release declared.
Commercial Significance
Drugs constitute one of the Britain's largest exports to the America, which is by far the largest market for major British pharmaceutical firms.
Trade data show that in the one-year period leading up to September, the UK shipped medicines worth over eleven billion pounds to the US. This amount made up nearly one-fifth of British export trade in that timeframe.
"This deal protects employment, boosts capital expenditure and paves the way for the UK to emerge as a international leader for medical research," the Business and Trade Secretary remarked.
Detailed UK Commitments
The deal involves several key pledges from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new medicines to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a aim to raise overall health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to stay within budget will be limited at fifteen percent. Previously, repayments were more than twenty percent.
Industry Background
The pact takes place against a long-running row between the drug companies and the British authorities over spending levels and NHS adoption.
This friction were heightened by claims that US consumers were charged significantly more for the equivalent treatments than patients in the other developed nations.
Recently, several significant pharmaceutical investments in the UK have been delayed or abandoned, while substantial funding commitments have been announced toward American operations.
A senior figure acknowledged that the NHS needed to spend more on treatments, noting that its spending on drugs had decreased as a proportion of its resources over the past decade.
